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S U M M A R Y
Background: In 2010, there was an increase in enterovirus meningitis in the province of Ontario, Canada.
Concurrently, there was also an increase in coxsackievirus A9-positive specimens in Alberta, Canada.
This study aimed to describe the results of an investigation into the increase in coxsackievirus (A9
serotype) in 2010 in Ontario.
Methods: For the purpose of this study, we report on specimens tested by viral culture at Public Health
Ontario Laboratory as part of routine laboratory testing from January 1, 2005 to December 31, 2011.
Results: Coxsackieviruses represented more than one third of enteroviruses detected, with A9 being the
serotype most commonly identiﬁed. The most common specimen source in which A9 was isolated was
cerebrospinal ﬂuid, followed by nasopharyngeal swabs and stool. Patients in whom A9 was detected
were older than individuals with any other coxsackievirus serotype.
Conclusions: The increase in enterovirus meningitis in Ontario in 2010 was likely due to an increase in A9
circulation. A9 was most commonly identiﬁed among children; however A9 may cause severe illness in
both children and adults. Monitoring the circulation and epidemiology of enteroviruses can inform
clinicians about circulating pathogens to optimize clinical testing and antibiotic use.
Crown Copyright  2014 Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).
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Human enteroviruses can cause a wide range of disease
severity, with febrile illness, irritability, lethargy, and hand, foot
and mouth disease (HFMD) being the most common clinical
presentations.1,2 Due to the mild nature of these symptoms,
disease incidence is often underestimated.1 Severe clinical
manifestations include aseptic meningitis, encephalitis, sepsis,
hepatitis, and myocarditis.3 The proliferation of enteroviruses
occurs primarily in the respiratory and gastrointestinal tracts.
Later, viremia may occur, resulting in spread to other body targets.4
Fecal–oral spread represents the main transmission pathway of
enteroviruses, although they can also be spread by respiratory
routes.3 Shedding in stool may last for up to 11 weeks, while
shedding through the respiratory tract often lasts for 1 week or
less.5 Individuals of all ages are susceptible to enterovirus
infection, however children and the immunocompromised are§ An earlier version of this paper was presented as a poster at the 27th Clinical
Virology Symposium, May 8–11, 2011, Daytona Beach, Florida, USA.
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).most vulnerable. These populations tend to shed the virus for
longer periods, hence may play an important role in disease
transmission.1,6
Coxsackieviruses are members of the Enterovirus genus in the
family Picornaviridae, which have been categorized into 23 group A
serotypes (A1–A22, A24) and six group B serotypes (B1–B6).7,8
Most of the epidemiologic and clinical characteristics of coxsack-
ieviruses are similar to other enteroviruses.9 Coxsackievirus A9
(A9) has been associated with various illnesses, with generalized
febrile exanthem being the most common.10 A9 is the most
commonly identiﬁed enterovirus associated with central nervous
system infections.8,11 Similar to other enteroviruses, A9 demon-
strates seasonal circulation patterns, with a peak incidence
occurring in the summer months in temperate climates.1,10 A9
has been identiﬁed in sporadic disease occurrence as well as
community outbreaks.12–14 The incidence of A9 has been reported
to be highest in infants and young children.3,9,10
In September 2010, an increase in the number of A9-positive
specimens was reported by the Provincial Laboratory in Alberta,
Canada.15 During that timeframe, staff at Public Health Ontario
were notiﬁed that three of Ontario’s 36 health units were
experiencing an increase in the number of cases of enterovirusSociety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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tion was launched at Public Health Ontario Laboratory (PHOL) to
determine if similar trends were being detected at our provincial
public health laboratories and we discovered an increased number
of A9 detections. The purpose of this study was to describe the
results of the investigation to determine if the increase was
associated with atypical ﬁndings.
2. Methods
For the purpose of this study, we report on specimens tested by
viral culture at PHOL as part of routine laboratory testing from
January 1, 2005 to December 31, 2011. Viruses were isolated from
various specimen types including nasal swabs, nasopharyngeal
(NP) swabs, throat swabs, cerebrospinal ﬂuid (CSF), auger suction
(pharyngeal aspirates), endotracheal aspirates, stool, skin swabs,
urine, and autopsy tissues. Primary screening for enteroviruses in
viral culture was based on the appearance of an enterovirus-like
cytopathic effect (CPE). Virus-infected cell cultures showing CPE
were conﬁrmed to contain enterovirus and serotyped using an
indirect immunoﬂuoresence assay (IFA). Rhesus monkey and WI-
38 cell lines were used for respiratory specimens and African green
monkey and MRC-5 cell lines for other specimen types. At PHOL,
reagents were available to identify coxsackieviruses A9, A16, B1,
B2, B3, B4, B5, and B6; echoviruses 4, 6, 9, 11, and 30; polioviruses
1, 2, and 3; and enteroviruses 70 and 71 (Light Diagnostics;
Millipore Bioscience Division, Temecula, CA, USA). Untypeable
isolates were then repassaged into fresh culture and examined by
electron microscopy (EM). If after the second passage the isolate
remained untypeable but was identiﬁed by EM as enterovirus, the
result was reported at the genus level as enterovirus for non-
respiratory specimens, and for respiratory specimens the result
was reported as enterovirus-like. A selection of culture-negative
CSF specimens from 2009 and 2010 were further evaluated by
enterovirus real-time reverse transcriptase PCR (rRT-PCR) with
primers targeting the 50-untranslated region (50-UTR). All entero-
virus PCR-positive specimens were molecularly typed by nested
RT-PCR targeting the viral capsid protein VP1 region and Sanger
sequencing.
2.1. Statistical analysis
Two different laboratory information systems were in place at
PHOL during the study period. Each viral culture database was ﬁrst
cleaned and then merged based on common variables including
patient demographics, local health unit of residence, specimenTable 1
Enterovirus serotypes detected in viral culture by year the specimen was received at P
Enterovirus 2005 2006 2007 
Coxsackievirus A9 2 3 21 
Coxsackievirus A16 0 1 0 
Coxsackievirus B1 0 1 15 
Coxsackievirus B2 5 5 4 
Coxsackievirus B3 4 6 0 
Coxsackievirus B4 5 2 12 
Coxsackievirus B5 24 1 3 
Echovirus 4 0 0 0 
Echovirus 6 5 4 2 
Echovirus 9 0 8 4 
Echovirus 11 0 2 0 
Echovirus 30 11 0 0 
Enterovirus 27 22 18 
Enterovirus 71 0 2 2 
Enterovirus-like 70 37 32 
Total enteroviruses/year 153 94 113 
Total specimens tested/year 18 807 19 137 19 145 
PHOL, Public Health Ontario Laboratory.source, test result, and date the specimen was received at PHOL.
Only positive specimens were analyzed to describe seasonal trends
and specimen sources, and patient-level analyses were performed
to describe demographics and geographic distribution, counting
only one positive specimen per patient per year.
Statistical analyses were performed using Stata/SE version 10.0
(StataCorp LP, College Station, TX, USA). The Chi-square or Fisher’s
exact test was used (the latter in the event of a small sample size)
to determine the association between detected coxsackieviruses
and month and year of detection, specimen source, patient age, sex,
and health unit of patient residence.
Additional descriptive analysis and a mixed logistic regression
model were performed on all patients who had at least one
coxsackievirus detected and multiple specimens submitted,
regardless of specimen result and episode for which the specimen
was submitted, to compare the likelihood of specimens from
various sources yielding a positive coxsackievirus result. Odds
ratios (OR) with 95% conﬁdence intervals (95% CI) were reported.
Using this model, any subsequent specimen submitted within a
90-day period from ﬁrst specimen submission was counted as part
of the ﬁrst episode. If the second or subsequent specimens were
submitted more than 90 days from the previous specimen, this was
considered as a separate episode. A lag period was calculated as the
difference in days between the ﬁrst and subsequently submitted
specimen(s).
3. Results
3.1. Specimen information: yearly and seasonal trends
From January 1, 2005 to December 31, 2011, 941 (0.5%)
specimens tested positive for enterovirus at PHOL, of which 334
(35.5%) specimens were coxsackieviruses (A9, A16, B1, B2, B3, B4,
and B5) (Table 1). A9 was the most frequently identiﬁed serotype,
identiﬁed in 103 (10.9%) of all enterovirus-positive specimens. In
addition, echoviruses (4, 6, 9, 11, and 30) were identiﬁed in 132
(14%) of all enterovirus-positive specimens, with echovirus 6 the
predominant serotype identiﬁed in 50 (5.3%) of all enterovirus-
positive specimens. Enterovirus 71 was detected in 9 (0.9%)
enterovirus-positive specimens and the remaining 466 (49.5%)
enterovirus-positive specimens were not typeable and reported as
enterovirus-like or enterovirus.
The distribution of coxsackievirus serotypes varied by calendar
year (p < 0.001). Seventy-nine percent of A9-positive specimens
were identiﬁed during 2007 and 2010; few A9 were identiﬁed inHOL; January 1, 2005 to December 31, 2011, Ontario, Canada
2008 2009 2010 2011 Total serotypes
3 8 60 6 103
1 5 10 0 17
2 14 3 4 40
2 29 0 2 47
1 3 0 3 17
5 13 5 17 59
2 5 7 9 51
3 2 1 4 10
4 0 31 4 50
1 25 7 2 47
2 4 0 2 10
1 3 0 0 15
9 12 11 9 108
0 1 2 2 9
47 32 98 42 358
83 156 235 106 941
26 163 47 820 21 621 26 843 179 536
Table 2
Percent positivity of all enteroviruses detected in cerebrospinal ﬂuid specimens; January 1, 2005 to December 31, 2011, Ontario, Canada
Cerebrospinal ﬂuid 2005 2006 2007 2008 2009 2010 2011 Total
Enterovirus-positive specimens 10 5 10 0 8 24 9 66
Total specimens tested 1347 1298 1202 1165 1087 995 990 8084
Percent positive 0.7 0.4 0.8 0.0 0.7 2.4 0.9 0.8
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2007 (21 specimens) and 2010 (60 specimens) were 4.8 times and
13.6 times, respectively, as high as the average number of A9-
positive specimens for other years (average 4.4 specimens, range
2–8). The increase in coxsackievirus A9 in 2010 also corresponded
with a four-fold increase in the detection of all enteroviruses in CSF
(2.4%) by viral culture compared to the average detection during
the rest of the period (0.6%) (Table 2). Testing of a selection of
culture-negative CSF specimens by molecular methods identiﬁed
3/148 (2%) culture-negative specimens positive for enterovirus in
2009 and 19/245 (7.7%) culture-negative specimens in 2010.
Molecular typing by VP1 sequencing was performed on 13 of the
enterovirus-positive CSF samples and conﬁrmed A9 in 10 speci-
mens and echovirus 6 in two; one could not be typed. Molecular
testing was not performed on any specimens from other study
years.
Other coxsackievirus serotypes and the year in which they
peaked included B5 (primarily identiﬁed in 2005), B2 (2009), and
B4 (2011). Similar to other enteroviruses, the frequency of
coxsackievirus detection was highest in the summer and fall
months; this was true for all years (p < 0.05) (Figure 1). The
incidence of A9 detection peaked in August–September, B2 in
September, B1 and B5 in August, and B4 in November, for all years.
While the identiﬁcation of A16 peaked in July and B3 in November,
counts for these two serotypes were low (n < 20), hence clear
seasonal patterns could not be discerned.
Of all coxsackieviruses detected, 119/334 (36%) were isolated in
NP swabs, 109/334 (33%) in stool, and 66/334 (20%) in CSF. The
remaining viruses were detected in throat swabs, mouth swabs,
skin scrapings, auger suction, nasal swabs, and urine (Figure 2).
Speciﬁc coxsackievirus serotypes were more likely to be detected
in certain specimen sources; this association was statistically
signiﬁcant (p < 0.001). The most common specimen source in
which A9 was isolated was CSF (36/103; 35%), followed by NP
swabs (29/103; 28%) and stool (25/103; 24%) (Figure 2). Stool was
the most common specimen source in which B3 and B5 were
identiﬁed, representing 8/17 (47%) and 27/51 (53%) of B1 and B3Figure 1. Coxsackievirus serotypes and other enteroviruses detected by month the sisolates, respectively. The NP swab was the most common
specimen source in which B1, B2, and B4 were isolated with 19/
40 (48%), 21/47 (45%), and 27/59 (46%) of B1, B2, and B4 isolates,
respectively, identiﬁed in NP swabs. A16 was mostly identiﬁed in
NP swabs and skin scrapings, representing the specimen source in
4/17 (24%) A16-positive specimens each.
3.2. Patient information: demographics
Between January 1, 2005 and December 31, 2011, 310 patients
tested positive for any coxsackievirus. The mean and median age of
patients in whom a coxsackievirus was detected (n = 299) was 7.6
and 2 years, respectively, with a range of 10 days to 80 years.
Coxsackieviruses were most frequently detected in children; 201/
310 (65%) patients were less than 4 years old and 93/310 (30%)
were less than 12 months old. Ninety-four (30%) patients tested
positive for the A9 serotype. A9 was the most common serotype
detected across all age groups except for those aged 1–4 years, for
whom B4 was the most common serotype (Figure 3). Patients in
whom A9 was detected were older than individuals with any other
coxsackievirus serotype identiﬁed; mean and median age was 12.3
and 4 years, respectively (p < 0.01). The age of patients in whom A9
was detected in 2010 was not different compared to those who had
A9 isolated in any other year (p > 0.05).
Of the 290 coxsackievirus-positive patients for whom sex was
reported, 174 (60%) were male and 116 (40%) were female; this did
not achieve statistical signiﬁcance. A similar sex distribution was
observed among patients in whom A9 was detected; 57/87 (66%)
were males and 30/87 (34%) were females.
More than half of the patients (153/310) in whom any
coxsackievirus was identiﬁed were from Toronto (78/310; 25%),
Peel (28/310; 9%), Halton (27/310; 9%), and Niagara (20/310; 7%)
health units; however this was congruent with their respective
proportionate populations in Ontario. Other patients were
randomly distributed across Ontario. A similar distribution in
health unit of residence was observed among A9 patients during all
years, as well as during the increase in 2010 (p > 0.05).pecimen was received; January 1, 2005 to December 31, 2011, Ontario, Canada.
Figure 2. Coxsackievirus serotypes by specimen source; January 1, 2005 to December 31, 2011, Ontario, Canada.
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Eighty-two (27%) of the 310 patients in whom coxsackieviruses
were detected had more than one specimen submitted, with
a range of one to six specimens submitted per patient, for a total
of 197 specimens; coxsackieviruses were detected in 106 of
these specimens. However, not all specimens were submitted at a
single point in time. Fifty-seven (69%) of the 82 patients had
multiple specimens submitted as part of a single episode, 22/82
(27%) had specimens submitted during two separate episodes, and
3/82 (4%) patients had specimens submitted as part of three or
more episodes. Of all multiple specimens submitted as part of the
same episode (n = 160 specimens), 125 (78%) specimens were the
ﬁrst submitted specimen or had a lag time of 0–2 days from the
ﬁrst submitted specimen and 35 (22%) specimens had a lag time of
more than 2 days (range 0–71 days). In addition, 64/82 (78%)
patients had multiple specimens submitted during the same
episode and 18/82 (22%) patients had a single specimen submitted
for different episodes. The most common combination of specimen
types collected for multiple submissions during the same episode
was NP swab/stool specimens submitted for 12/64 (19%) patients,
followed by CSF/stool specimens in 7/64 (11%) patients. Interest-
ingly, not all specimens submitted as part of the same episode
yielded a positive result. For example, off 12 patients who had both
an NP swab and stool collected, only the NP swab yielded a positive
result in two patients and only stool yielded a positive result in
another two patients; both specimen sources were positive in eight
patients. Among patients who had CSF/stool specimens collected,
only CSF yielded a positive result in one patient, only stool in fourFigure 3. Number of patients with coxsackievirus detected, by serotype and age;
January 1, 2005 to December 31, 2011, Ontario, Canada.patients, and both specimen sources in two patients. For three
patients, specimens collected from the same body site on the same
day or within a 0–2-day lag period did not yield the same test
results. One patient had two CSF specimens submitted on the same
day and only one was positive for coxsackievirus. The second
patient had two stool specimens submitted 1 day apart and only
the earlier specimen yielded a positive coxsackievirus result. The
last patient had two NP specimens submitted 2 days apart and only
the earlier one yielded a positive result.
A mixed logistic regression model was run to compare results of
multiple submissions for the same patient episode (n = 160)
adjusted for lag period and specimen source. We found that second
and subsequent specimens submitted within 0–2 days from the
ﬁrst specimen submitted were more likely to yield a positive result
than those submitted after 2 days (OR 3.13, 95% CI 1.33–7.37).
Among patients who had more than one specimen collected within
the same episode, stool specimens were more likely to yield a
positive coxsackievirus result than NP swab specimens (OR 4.12,
95% CI 1.68–10.08). This relationship was not signiﬁcant for CSF
(p > 0.05). When comparing positive results for specimens
collected for different episodes, no patient had a coxsackievirus
isolated more than once during the entire study period.
4. Discussion
Monitoring the epidemiology and types of circulating enter-
oviruses over time is important for the early identiﬁcation of new
serotypes or more virulent strains and the detection of disease
clusters associated with speciﬁc serotypes; our study included 7
years of laboratory surveillance data. Coxsackieviruses repre-
sented more than one third of enteroviruses identiﬁed, with A9
being the most common serotype, followed by B4, B5, and B2. A9
was responsible for the increase in enterovirus meningitis in
Ontario. Concurrently, A9 was reported to be associated with the
increase in aseptic meningitis in Alberta, Canada.15 Globally,
various coxsackievirus serotypes have been reported to circulate in
different geographic areas. For example A16, B3, B5, and A10 were
reported to be the most dominant serotypes in Taiwan from 1999
to 2006, and B5, B2, and A9 were the most common coxsackievirus
serotypes in the USA during 1970–2005.3,16
In our study, the circulation of coxsackieviruses in general and
the A9 serotype in particular demonstrated yearly variability. A
higher frequency of A9-positive samples was identiﬁed in 2007
and 2010, with the highest frequency in 2010. The increased
detection did not appear to be related to an increase in testing, as
A. Peci et al. / International Journal of Infectious Diseases 25 (2014) 136–141140the number of specimens tested in each of these 2 years was lower
than the annual average number of specimens tested for the entire
study period; 19 145 and 21 621 specimens versus 25 647
specimens, respectively. The A9 serotype has been reported
previously in the USA as a serotype with endemic patterns of
circulation, described as circulating at low levels with a few
distinct peaks.16 It is unclear why some serotypes dominated in
speciﬁc years, but population immunity to speciﬁc serotypes in
addition to the emergence of new lineages or re-emergence of
genotypes that circulated in the past are believed to inﬂuence
circulation patterns.16 Genomic sequencing of a set of isolates from
the A9 outbreak in Alberta in 2010 found that A9 displayed signs of
recombination and genetic divergence in the VP4 region, but the
sequence was conserved in the antigenic regions of the VP1, VP2,
and VP3 genes. This ﬁnding supports the theory that the increase
was not as a result of the emergence of a new A9 mutant, but likely
occurred due to a decline in herd immunity against this serotype.15
All coxsackieviruses including A9 primarily circulate in the
summer and fall; this has been well established.3,10,17
Coxsackieviruses were most commonly isolated in NP swab
specimens, followed by stool and CSF. A9 was primarily isolated in
CSF and the same pattern was observed during the peak in 2010.
The increased detection of enteroviruses in CSF supports the
observation that there was an increase in enterovirus meningitis in
Ontario, Canada in 2010. CSF followed by respiratory specimens
and stool have been reported elsewhere as the most common
specimen sources in which coxsackieviruses were detected.
However, these surveillance data have some limitations due to
incompleteness of reporting and variations between testing
procedures between laboratories, which may affect the results.16
Isolation from CSF conﬁrms disease etiology and likely represents
severe disease due to a central nervous system infection, however
virus identiﬁcation from this source is impacted by the frequency
of use of such an invasive procedure.18 Other studies have reported
CSF, throat swabs, and stool specimens as the most common
sources for the detection of B serotypes; however these studies
reported only positive results and not positive isolation rates.17 In
our study, only 3% of all coxsackieviruses and 4% of A9 were
detected from throat swabs. Similar to other enteroviruses, the
detection of coxsackieviruses in non-sterile sites may conﬁrm the
presence of the virus, but may not necessarily be the causative
organism of acute infection because children and the immuno-
compromised shed the virus from stool for many weeks after
disease onset.1,6
Consistent with previous reports, coxsackieviruses were most
frequently detected among infants and children; however, patients
in whom the A9 serotype was detected were older than patients
who had any coxsackievirus isolated.3,9,10,16 The wide age
distribution of patients in whom A9 was detected in addition to
the fact that A9 was primarily found in CSF supports that A9 may
be the cause of severe disease across all age groups.17 However,
this may reﬂect a testing bias, as children are more likely to be
tested for enterovirus when they experience milder illness, while
adults only tend to undergo laboratory testing when they present
with more severe illness.17
Some published studies have reported a male predominance in
patients with coxsackieviruses, but statistical signiﬁcance was not
determined.3,9,16 In our study, the highest proportions of
individuals in whom any coxsackievirus or the A9 serotype was
detected were male; however, this did not achieve statistical
signiﬁcance.
When more than one specimen was submitted for a patient,
specimens with a shorter lag period (0–2 days) were more likely to
yield a positive coxsackievirus result compared to those submitted
more than 2 days after the previous specimen. This highlights the
importance of early submission of specimens for viral detection. Inaddition, the specimen source in which coxsackieviruses were
most likely to be detected was stool, followed by NP swab. This
may be due to the fact that like enteroviruses, coxsackieviruses are
shed for longer periods in stool than through respiratory pathways,
or to the fact that physicians collect more stool and NP specimens
from people presenting with enterovirus-like symptoms, hence
allowing more opportunity for detection.19 There was no differ-
ence in the yield of positive results between CSF and NP swab. The
date of symptom onset was not consistently reported by specimen
submitters, so our model could not adjust for symptom onset to
specimen collection times.
Our study has a number of limitations. The coxsackieviruses
reported may not represent all circulating coxsackieviruses. Most
people who have a coxsackievirus infection manifest mild illness
and do not seek medical care, and thus do not undergo laboratory
testing.2 PHOL uses viral culture to test for enteroviruses, which
are known to be difﬁcult to grow in this medium.19 While PHOL
performs the majority of testing for enteroviruses in Ontario, other
community and hospital laboratories perform these tests, with
many using molecular testing rather than culture. Therefore, the
numbers reported here do not represent the total number of
enteroviruses identiﬁed in all Ontario laboratories. However, the
use of molecular testing and sequencing in a subset of CSF
specimens did detect more enteroviruses in 2010 but also
conﬁrmed that A9 was the predominant enterovirus causing
aseptic meningitis in 2010. Additionally, PHOL does not test for all
coxsackievirus A serotypes, therefore we are unable to report on
the incidence of all serotypes. Speciﬁcally, we were unable to
appreciate the role of A6 in causing atypical HFMD, the occurrence
of which was recently reported in the USA.20 We were unable to
report overall percent positivity for coxsackieviruses because
specimens tested by viral culture may have been collected for
reasons other than enterovirus-related symptoms. Hence our
denominator data are not speciﬁc to enterovirus-related disease.
Finally, PHOL does not collect detailed clinical information and we
were unable to ascertain if disease severity was caused by
coxsackieviruses or another etiology.
In conclusion, this study documented historical trends in
Ontario of enteroviruses and coxsackievirus A9 in particular. In
2010, there was an increase in enterovirus meningitis in the
province of Ontario, Canada, which was likely due to random
yearly variability of A9 circulation, which also increased in 2010.
Similar to other coxsackieviruses, A9 was most commonly
identiﬁed among children, but may cause severe illness in both
children and adults. Early specimen collection is recommended to
optimize virus detection. Monitoring the circulation and epidemi-
ology of enteroviruses can inform clinicians about circulating
pathogens to optimize clinical testing and antibiotic use.
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